Relief Therapeutics gets review board nod for trial of blood cancer therapy

Jan. 17, 2023 4:48 AM ETRelief Therapeutics Holding AG (RLFTF), RLFTYBy: Ravikash, SA News Editor

Medical Science Laboratory: Portrait of Beautiful Black Scientist Looking Under Microscope Does Analysis of Test Sample. Ambitious Young Biotechnology Specialist, working with Advanced Equipment


  • Relief Therapeutics (OTCQB:RLFTF) (OTCQB:RLFTY) said it received independent institutional review board (IRB) approval for the protocol of a trial of RLF-TD011 as an adjunctive treatment for patients with cutaneous t-cell lymphoma (CTCL).
  • The Swiss company added that the investigator-initiated

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.